IceCure Medical
IceCure Medical develops and markets the ProSense Cryoablation System, a liquid nitrogen-based medical device for minimally invasive tumor destruction in breast cancer, kidney cancer, lung cancer, and fibroadenomas, serving hospitals, cancer centers, breast surgeons, and interventional radiologists globally.
- Company typePublic
- Founded2006
- HeadquartersCaesarea, Israel
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What IceCure Medical does
IceCure Medical Ltd. is an Israeli medical device company founded in 2006 that develops and markets the ProSense Cryoablation System, a liquid nitrogen-based platform that destroys tumors by generating ultra-cold temperatures below -170°C. The system uses a single cryoprobe design that can be relocated up to three times per patient during a procedure, creating large lethal ice balls under imaging guidance. ProSense received FDA De Novo marketing authorization in October 2025 as the first and only device cleared for the local treatment of early-stage low-risk breast cancer in women aged 70 and above. Additional clinical applications include kidney cancer, lung cancer, liver tumors, musculoskeletal tumors, palliative care, and benign breast fibroadenomas. The company is publicly traded on Nasdaq (ICCM) and the Tel Aviv Stock Exchange, headquartered in Caesarea, Israel, with 51–100 employees.
The company operates a capital equipment plus disposable consumables business model, generating revenue from sales of the ProSense console and recurring single-use cryoprobes. FY2025 revenue was $3.4 million, up 3% from $3.3 million in 2024, with gross margin declining to 36% from 44% due to increased raw material and subcontractor costs. Net loss for 2025 was approximately $15.1 million. The company uses direct sales in the United States targeting hospitals, cancer centers, breast surgeons, and interventional radiologists, and exclusive distribution partners internationally including KTR Medical in Brazil and Terumo Corporation in Japan. Breast cancer cryoablation procedures are reportable under CPT code 0581T with approximately $4,000 facility fee reimbursement.
The company's clinical evidence base includes the ICE3 trial (206 patients across 19 U.S. sites showing 3.1% local recurrence rate at 5 years), the ICESECRET kidney cancer trial (114 patients showing 89.4% recurrence-free rate at 5 years for tumors ≤3 cm), and the FDA-approved ChoICE post-marketing study (planned 400 patients across 30 U.S. sites). Key commercial and clinical sites include Cleveland Clinic, University of Michigan, Massachusetts General Hospital, West Cancer Center, Adventist Health Glendale, and Thomas Hospital. The company holds patents on next-generation XSense cryogenic connector and cryogenic pump technology in the U.S., Europe, and Japan through 2041, and has raised approximately $25 million across multiple financing rounds in 2025–2026 to support commercial expansion.
IceCure Medical firmographics
Firmographics- Name
- IceCure Medical
- Legal name
- IceCure Medical Ltd.
- Website
- https://icecure-medical.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- IceCure Medical develops and markets the ProSense Cryoablation System, a liquid nitrogen-based medical device for minimally invasive tumor destruction in breast cancer, kidney cancer, lung cancer, and fibroadenomas, serving hospitals, cancer centers, breast surgeons, and interventional radiologists globally.
- Ownership category
- akta.pro rank
IceCure Medical industry classification
Industry- Product category
- Cryoablation Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)
Keywords
Where IceCure Medical is headquartered
LocationHeadquarters
- HQ city
- Caesarea
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
IceCure Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- ProSense System and Cryoprobe Sales: IceCure generates revenue through the sale of ProSense cryoablation systems (capital equipment) and disposable cryoprobes. 2025 full-year revenue was $3.4 million, up 3% from $3.3 million in 2024. North America sales grew 42% in 2024.
- System Sales and Probe Revenue: The company expects U.S. revenue from ProSense systems and cryoprobes to increase more than 30% in Q1 2026 compared to Q1 2025. The company projects continued commercial momentum in 2026 with additional reimbursement coverage expected.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Reimbursement code for breast cancer cryoablation procedure |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
IceCure Medical product offering
Product offeringCore offering
IceCure Medical develops, manufactures, and commercializes the ProSense Cryoablation System, a liquid nitrogen-based medical device platform that uses ultra-cold temperatures (below -170°C) to minimally invasively destroy tumors via a single cryoprobe. The system is sold as capital equipment with disposable cryoprobes to hospitals, cancer centers, and clinics, with FDA clearance for low-risk breast cancer and additional regulatory approvals for kidney, lung, liver, and musculoskeletal tumors globally.
Product overview
IceCure Medical offers the ProSense Cryoablation System as its flagship product, a liquid nitrogen-based medical device platform that provides minimally invasive tumor destruction through freezing technology. The system includes the main console unit, single cryoprobes, and is supported by next-generation XSense cryogenic connector technology. ProSense is FDA-cleared for breast cancer treatment and has regulatory approvals for kidney, lung, liver, and other tumor applications across global markets.
Differentiator
Problem solved
Functional benefit
Brands
- ProSense: Liquid nitrogen-based cryoablation system for tumor destruction, FDA-cleared for low-risk breast cancer treatment
- XSense
Products and services
- ProSense Cryoablation System A liquid nitrogen-based cryoablation system that destroys tumors by freezing them using ultra-cold temperatures lower than -170°C, creating large lethal ice balls for tumor destruction in benign and cancerous lesions including breast, kidney, lung, and liver tumors. Sold to hospitals, cancer centers, and clinics for outpatient cryoablation procedures.
- ProSense Cryoprobes Single cryoprobe system available in various sizes that can be relocated up to three times per patient during a single procedure to treat larger tumors or multiple lesions. Sold as disposable consumables to accompany the ProSense capital equipment.
- XSense Cryogenic Connector Technology Next-generation cryoablation technology featuring improved cryogenic pump technology and cryogenic system connector designed to enhance safety and cooling rates in cryoablation procedures. Designed to integrate with the ProSense cryoablation platform.
Quantifiable outcome
- 3.1% local recurrence rate within 5 years for breast cancer patients treated with cryoablation and endocrine therapy (ICE3 trial)
- +7 more outcomes
Companies that use IceCure Medical
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles2 records
IceCure Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
IceCure Medical partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- KTR MedicalcoreKTR Medical serves as the exclusive importer and distributor of IceCure's ProSense cryoablation system in Brazil. The partnership has enabled commercial procedures for breast, lung, kidney cancer, and musculoskeletal tumors at key Brazilian medical centers following FDA authorization. An independent 750-patient study (SIX trial) led by Dr. Vanessa Sanvido is underway in Brazil.
- Terumo CorporationcoreTerumo Corporation is IceCure's exclusive distributor in Japan. The company participated in the Japanese Breast Cancer Society Conference presenting clinical data. Terumo is expected to submit ProSense for regulatory approval to Japan's PMDA in H2 2026 for breast cancer indication.
Scale indicators14 records
Recent moves8 records
Expansion highlights8 records
IceCure Medical competitors and assessment
Company assessmentDirect peers
- HealthTronics: HealthTronics provides cryoablation services and equipment for urology and oncology, including prostate and kidney tumor treatments. As a service-and-device operator in the same cryoablation category, it overlaps with ProSense's interventional radiology use cases.
- AngioDynamics: AngioDynamics manufactures cryoablation systems (Cryo-Hit, Endocare product lines) used for prostate, kidney, and other tumor ablation. It is a direct competitor to IceCure's ProSense in the cryoablation device market, with established US sales coverage in interventional oncology.
- Boston Scientific (Galil Medical): Boston Scientific acquired Galil Medical, a pioneer in argon-based cryoablation technology for kidney, prostate, and other tumors. As the largest incumbent in percutaneous cryoablation, it competes directly with ProSense in interventional radiology suites globally.
Broad incumbents
- Varian Medical Systems (Siemens Healthineers): Varian is a leading radiation oncology and interventional oncology platform serving hospitals treating breast, lung, and other solid tumors. As an established incumbent in the broader oncology treatment device market, it competes indirectly with ProSense for capital budgets and physician mindshare.
- Medtronic: Medtronic operates a large interventional oncology and minimally invasive therapies franchise including ablation technologies. It is a broad incumbent that competes with ProSense across multiple tumor types via its established global sales infrastructure and hospital relationships.
- Hologic: Hologic is a major women's health company with breast biopsy, diagnostics, and breast surgery products. It serves the same breast surgeon customer base as IceCure and is a broad incumbent in the breast cancer workflow where ProSense cryoablation competes as a treatment alternative.
Emerging players
- EDAP TMS: EDAP TMS markets HIFU (high-intensity focused ultrasound) ablation devices, primarily for prostate cancer and other urological conditions. It is an emerging player in non-surgical tumor ablation, sharing IceCure's strategy of displacing surgery with minimally invasive ablative therapy.
- Sensus Healthcare: Sensus Healthcare markets superficial radiation therapy (SRT) systems used for non-melanoma skin cancer and is exploring breast cancer indications. It is an emerging player pursuing minimally invasive office-based alternatives for cancer treatment, with overlapping physician adoption dynamics.
- Merit Medical Systems: Merit Medical manufactures interventional radiology and oncology devices, including ablation and embolization products. It overlaps with ProSense in serving interventional radiologists who perform percutaneous tumor ablations across kidney, lung, and other solid tumors.
Others
- Integra LifeSciences: Integra LifeSciences produces a broad portfolio of surgical, neurosurgical, and regenerative tissue products. It is an adjacent medical device manufacturer serving surgical oncology and interventional specialists, but does not directly compete in cryoablation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
IceCure Medical social profiles
Digital presenceIceCure Medical compliance and trust
Trust signalCompliance7 records
IceCure Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
IceCure Medical leadership team
Management profileNumber of profiles
Profiles6 records
IceCure Medical funding detail
Funding detailFunding overview
Funding rounds10 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IceCure Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IceCure Medical
What does IceCure Medical do?
IceCure Medical develops, manufactures, and commercializes the ProSense Cryoablation System, a liquid nitrogen-based medical device platform that uses ultra-cold temperatures (below -170°C) to minimally invasively destroy tumors via a single cryoprobe. The system is sold as capital equipment with disposable cryoprobes to hospitals, cancer centers, and clinics, with FDA clearance for low-risk breast cancer and additional regulatory approvals for kidney, lung, liver, and musculoskeletal tumors globally.
Is IceCure Medical a public or private company?
IceCure Medical is a public company. It is classified as public and is currently operating.
When was IceCure Medical founded?
IceCure Medical was founded in 2006. It employs 51 to 100 people.
Where is IceCure Medical based?
IceCure Medical is headquartered in Caesarea, Israel, in the Middle East region.
How does IceCure Medical make money?
Two revenue lines are on record. ProSense System and Cryoprobe Sales are the primary driver. The others are system Sales and Probe Revenue.
Who are IceCure Medical's main competitors?
Direct peers on record are HealthTronics, AngioDynamics and Boston Scientific (Galil Medical). Broad incumbents are Varian Medical Systems (Siemens Healthineers), Medtronic and Hologic. Emerging players are EDAP TMS, Sensus Healthcare and Merit Medical Systems. Integra LifeSciences is listed as an others.
Does IceCure Medical have an API?
No public API is recorded for IceCure Medical.
What industry is IceCure Medical in?
IceCure Medical's product category is Cryoablation Medical Devices. Its primary akta.pro industry code is HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats). Its NAICS code is 3391 and its SIC code is 3841.